Infectious Disease Clinics of North America volume 19, issue 2, P415-425 2005 DOI: 10.1016/j.idc.2005.04.005 View full text
|
|
Share
Steven J. Reynolds, Thomas C. Quinn

Abstract: Antiviral agents aimed at treating HSV-2 chronically infected individuals have proven to be effective in the prevention of symptomatic genital herpes and the reduction of viral shedding. These agents play a key role in current HIV prevention trials that will assess the role of suppression of HSV-2 infection on the risk for HIV acquisition and transmission. An added clinical benefit of treating HSV-2/HIV-coinfected individuals is the potential survival benefit, as suggested by earlier studies and by the recent …

expand abstract